Achievements

Intro text: 

Much of BIG’s research is considered to be landmark, introducing particularly innovative designs, contributing to significant breakthroughs, or paving the way towards more personalised treatment of the disease.

These studies have already made an impact, or that we expect to in the future:

Content: 

 

 

The results of this study could influence how 2 in 5 women with breast cancer are treated by identifying which women could be spared unnecessary radiation therapy after surgery in the future.

Learn more here

Content: 

 

POSITIVE represents a unique opportunity to allow young women who have had hormone sensitive breast cancer to temporarily interrupt their treatment and try to conceive.

Learn more here

Content: 

 

 

The AURORA research programme aims to better understand the molecular characteristics and evolution of recurrent or metastatic breast cancer, in the hope of treating more effectively, and possibly blocking the disease in the future.

Learn more here

Content: 

 

 

The international randomised SOFT & TEXT clinical trials offer a new post-operative treatment option for young women with hormone-sensitive early breast cancer. 

Learn more here

Content: 

The APHINITY trial found that adjuvant pertuzumab in combination with trastuzumab and chemotherapy in patients significantly improved the rates of invasive-disease-free survival among patients with HER2-positive, operable breast cancer when it was added to trastuzumab and chemotherapy.

 

Learn more here.

Content: 

 

 

The MINDACT trial found that 46% of patients identified as high-risk for cancer recurrence based on traditional factors were identified as lowrisk when adding the MammaPrint test. It represents a large academic effort towards de-escalating therapies.

Learn more here.

Content: 

 

The ALTTO and NeoALTTO trials represent a valuable resource for translational research as well as large scale academic collaboration. 

Learn more here.

 

Content: 

 

The HERA trial indicated that one eyar of treatment with trastuzumab had a significant and sustained benefit in preventing cancer recurrence, thus settning a new standard treatment for HER+ breast cancer.

Learn more here.

Content: 

 

 

The BIG 1-97, BIG 2-97 and BIG 1-98 trials contributed to the body of evidence that aromatase inhibitors could be used as a safe alternative to tamoxifen.

Learn more here.